GLP-1 weight loss.
Prescribed here, inside a programme — testing, training and follow-up. Not a form, a shipment, and good luck.
A medication inside a programme.
GLP-1 receptor agonists mimic a hormone the gut releases after a meal. They slow gastric emptying, act on the brain's appetite regulation, and improve the insulin response to food. For most people the subjective change is a quieting of what patients often call food noise — the constant background negotiation about eating.
They work. That is not in dispute, and it is also not the interesting part. What determines whether someone is better off in three years is what happens around the medication: whether lean tissue was preserved, whether metabolic health improved rather than just body weight, and whether anything changed about the conditions that produced the problem.
That is why the medication always comes with the programme around it. Every patient gets bloodwork including fasting insulin, a metabolic assessment, a resistance training plan, protein targets, and structured follow-up. The medication makes the behavioural work possible; the behavioural work is what makes the result durable.
Prescribing happens in-house at both our Jacksonville and Orange Park locations, after an evaluation — not before one.
History, contraindication screening, and bloodwork including fasting insulin alongside glucose — because insulin reveals the metabolic picture long before glucose does. We establish whether a GLP-1 is appropriate for you at all, and whether something else is driving the picture. Thyroid dysfunction, sleep apnea and medication effects all deserve ruling out first.
The muscle problem nobody mentions
Any substantial weight loss includes some lean tissue, and rapid loss without a training stimulus tends to include proportionally more. That matters more than the aesthetics suggest.
Skeletal muscle is the largest site of glucose disposal in the body. Losing it reduces your capacity to handle carbohydrate, which is the opposite of what someone with insulin resistance needs. It also lowers resting energy expenditure, making the weight easier to regain and the next attempt harder.
This is the strongest argument for treating GLP-1 therapy as one component rather than the whole intervention. Resistance training and adequate protein are what keep the loss weighted toward fat, and they need to be running from the start rather than added once the scale stalls.
Built so the results hold
The reason our programme is built the way it is comes down to one idea: what you build while you are on the medication is what you keep.
So the medication is only part of it. Alongside it we build muscle through resistance training, improve insulin sensitivity, sort out sleep and stress, and establish eating patterns that work without white-knuckling them. Those changes belong to you, and they stay.
That is also why we plan the transition from the very first visit rather than leaving it as an afterthought. Whether that means a maintenance dose, a taper, or coming off entirely, it is a decision we make together based on your markers and what you have built — and you go into it with a plan already in place.
Side effects and how we manage them
Gastrointestinal effects are the most common: nausea, reflux, constipation, and appetite suppression that can overshoot into inadequate intake. Most are dose-related, and the single most effective management strategy is unhurried titration.
Inadequate protein intake is a frequent and under-recognised problem — when appetite drops sharply, people often reduce protein first, which is precisely backwards given the muscle-preservation priority. We track this deliberately.
More serious considerations exist. Pancreatitis is a recognised risk. Gallbladder issues can accompany rapid weight loss. There are absolute contraindications relating to personal or family history of medullary thyroid carcinoma and MEN2. These are screened at evaluation, which is a large part of why an evaluation is not optional.
Why we test insulin, not just weight
Weight is a crude proxy for metabolic health. Someone can lose weight while losing muscle and worsening their glucose disposal capacity, and the scale will show progress.
We measure fasting insulin alongside glucose, HbA1c, and a full lipid picture, and we repeat them. Improvement in those markers is what indicates the metabolic situation is genuinely changing rather than the number simply being lower.
It also catches cases where a GLP-1 is not the right answer at all. Someone whose weight is driven mainly by untreated sleep apnea or a thyroid problem needs that treated, and prescribing around it would be treating a symptom while leaving the cause running.